person · Reporting owner
Casdin Private Growth Equity Fund, L.P.
Disclosed activity across 4 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Absci CorpABSI · Entity 4685 | Director | July 26, 2021 | July 28, 2021 |
| STANDARD BIOTOOLS INC.LAB · Entity 6116 | Director | December 02, 2025 | December 05, 2025 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | 10% owner | August 03, 2021 | August 04, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Absci Corp
Report date July 26, 2021 · Filed July 28, 2021
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 6,745,333 |
Last balance in matching sequence
After 2021-07-26 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2021-07-26 · Conversion · Acquired 4,209,573 · Balance 4,209,573 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 2 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 5,182,833 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Row 3 · 2021-07-26 · Purchase · Acquired 1,562,500 · Balance 6,745,333 F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 973,260 |
Reported balance
After 2021-07-26 transaction · row 4
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 4 · 2021-07-26 · Conversion · Acquired 973,260 · Balance 973,260 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
| Series E Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-07-26 · Conversion · Disposed 1,274,431 · Balance 0 F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | Direct | 0 |
Reported balance
After 2021-07-26 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports |
| Convertible NoteSEC Table II · derivative / convertible security · Conversion / exercise price $13.12 | IndirectSee footnote | 0 |
Reported balance
After 2021-07-26 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2021-07-26 · Conversion · Disposed Not disclosed · Balance 0 F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date.
F2: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports
F3: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration.
F4: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports.
STANDARD BIOTOOLS INC.
Report date December 02, 2025 · Filed December 05, 2025
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, Casdin Partners GP, LLC, Casdin Private Growth Equity Fund II, L.P., CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC, Casdin Private Growth Equity Fund II GP, LLC, Casdin Eli
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,875,000 |
Reported balance
After 2025-12-02 transaction · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · 2025-12-02 · Purchase · Acquired 125,000 · Balance 71,875,000 F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 71,950,000 |
Reported balance
After 2025-12-03 transaction · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · 2025-12-03 · Purchase · Acquired 75,000 · Balance 71,950,000 F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 72,100,000 |
Reported balance
After 2025-12-04 transaction · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · 2025-12-04 · Purchase · Acquired 150,000 · Balance 72,100,000 F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 13,939,637 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 13,939,637 F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | IndirectSee footnote | 2,744,219 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 2,744,219 F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. |
| Common Stock, $0.001 par value per shareSEC Table I · non-derivative | Direct | 2,901,062 |
Reported balance
Holding disclosure · report date 2025-12-02 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,901,062 F5: The securities are owned directly by Eli Casdin. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4050 to $1.4351. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F2: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4403 to $1.4406. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $1.4331 to $1.4588. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote.
F4: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC ("Casdin"), the investment adviser to the Master Fund, (ii) Casdin Partners GP, LLC (the "GP"), the general partner of the Master Fund, and (iii) Eli Casdin, the managing member of Casdin and the GP.
F5: The securities are owned directly by Eli Casdin.
F6: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin.
F7: The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin.
Tenaya Therapeutics, Inc.
Report date August 03, 2021 · Filed August 04, 2021
Jointly reported with Casdin Partners Master Fund, L.P., Casdin Capital, LLC, CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 2,374,849 |
Reported balance
After 2021-08-03 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2021-08-03 · Conversion · Acquired 2,374,849 · Balance 2,374,849 F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 3,224,849 |
Reported balance
After 2021-08-03 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2021-08-03 · Purchase · Acquired 850,000 · Balance 3,224,849 F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnotes | 361,969 |
Reported balance
After 2021-08-03 transaction · row 3
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 3 · 2021-08-03 · Conversion · Acquired 361,969 · Balance 361,969 F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). |
| Series B Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-08-03 · Conversion · Disposed 2,012,880 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-08-03 · Conversion · Disposed 361,969 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. |
| Series C Preferred StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | IndirectSee Footnotes | 0 |
Reported balance
After 2021-08-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-08-03 · Conversion · Disposed 361,969 · Balance 0 F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). |
Filing footnotes · ownership attribution and instrument terms
F1: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF).
F2: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any.
F3: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF).
F4: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Verve Therapeutics, Inc.
Report date June 21, 2021 · Filed June 22, 2021
Section 16 reporting ended · disclosed 2021-06-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 620,571 |
Reported balance
After 2021-06-21 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-06-21 · Conversion · Acquired 620,571 · Balance 620,571 F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2: The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-06-21 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-06-21 · Conversion · Disposed 5,746,183 · Balance 0 F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2: The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date.
F2: The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 17, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 352,072 | $2.56 | $902,043.67 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,375,821 F4 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5798. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 16, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $2.54 | $1,270,950.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 45,023,749 F3 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5381 to $2.5429. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| May 15, 2024 Filed May 18, 2024 00:11 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 500,000 | $2.57 | $1,282,550.00 |
DisclosureSEC source: 0000919574-24-003252 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Eli · CIK 0001534264 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote. Disclosed balance after: 44,523,749 F1 · price: The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions within the range of $2.5473 to $2.58. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares bought at each separate price within the range set forth in this footnote. F2 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 38,334 | $2.75 Strike: $2.75 | $105,418.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 8 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 13,939,637 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | Disposition to issuerSeries B-1 Convertible Preferred Stock · Derivative | 89,446 | $2.75 Strike: $2.75 | $245,976.50 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · derivative · entry 7 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,525,821 shares Expires not disclosed F7 · derivative.exercise_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F7 · derivative.expiration_date: Each share of the Issuer's Series B-1 Convertible Preferred Stock (the "Series B-1 Preferred Stock") was convertible at the option of the Reporting Person at any time into a number of shares of the Issuer's common stock, par value $0.001 per share. F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 13,939,637 | $2.75 | $38,334,001.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 13,939,637 F2 · ownership.nature: The securities are owned directly by Casdin Private Growth Equity Fund II, L.P. (the "Equity Fund II") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund II, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 21:54 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 32,525,821 | $2.75 | $89,446,007.75 |
DisclosureSEC source: 0000919574-24-002115 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 44,023,749 F1 · ownership.nature: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 00:20 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 1,403 | $2.62 | $3,668.85 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,497,928 F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 00:20 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | PurchaseCommon Stock | 250,000 | $2.57 | $642,500.00 |
DisclosureSEC source: 0000919574-24-001888 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Eli · CIK 0001534264 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,496,525 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions within the range of $2.5525 to $2.616. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2 · ownership.direct: The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 2,744,219 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 2,744,219 F2 · price: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. F2 · ownership.nature: Received in exchange for 2,472,270 shares of common stock of SomaLogic pursuant to the Merger. Per the terms of the Merger, each share of SomaLogic common stock was converted pursuant to the Exchange Ratio at the Effective Time. The securities are owned directly by Casdin Private Growth Equity Fund, L.P. (the "Equity Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin, the investment adviser to the Equity Fund, and (ii) Eli Casdin, the managing member of Casdin. Read SEC document |
| January 05, 2024 Filed Jan 10, 2024 01:51 UTC | STANDARD BIOTOOLS INC. LAB · Entity 6116 | GrantCommon Stock | 11,246,525 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000919574-24-000224 · ownership.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director · 10% owner Casdin Capital, LLC · CIK 0001534261 · Director · 10% owner Casdin Partners GP, LLC · CIK 0001534260 · Director · 10% owner Casdin Private Growth Equity Fund II, L.P. · CIK 0001891102 · Director Casdin Private Growth Equity Fund II GP, LLC · CIK 0001919480 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Casdin Partners FO1-MSV, LP · CIK 0001938709 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,246,525 F1 · price: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. F1 · ownership.direct: Received in exchange for 10,132,005 shares of common stock of SomaLogic, Inc. ("SomaLogic") pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated October 4, 2023, by and among Standard BioTools Inc. (the "Company"), Martis Merger Sub, Inc. and SomaLogic (the "Merger"). Per the terms of the Merger, each share of SomaLogic common stock was converted into the right to receive 1.11 shares of the Company's common stock (the "Exchange Ratio") at the effective time of the Merger (the "Effective Time"). The securities are owned directly by Casdin Partners Master Fund, L.P. (the "Master Fund") and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to the Master Fund ("Casdin"), (ii) Casdin Partners GP, LLC, the general partner of the Master Fund (the "GP"), and (iii) Eli Casdin, the managing member of Casdin and the GP. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | ConversionSeries C Preferred Stock · Derivative | 361,969 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · derivative · entry 6 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 361,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3 · ownership.nature: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | ConversionSeries C Preferred Stock · Derivative | 361,969 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · derivative · entry 5 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 361,969 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | ConversionSeries B Preferred Stock · Derivative | 2,012,880 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · derivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 0 Underlying: Common Stock · 2,012,880 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · price: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.exercise_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F4 · derivative.expiration_date: Each share of Series A Preferred Stock, Series B Preferred Stock and Series C Preferred Stock automatically converted into one share of common stock immediately prior to the completion of the Issuer's initial public offering, and had no expiration date. F1 · ownership.nature: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | ConversionCommon Stock | 361,969 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 361,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. F3 · ownership.nature: These shares are held directly by Casdin Private Growth Equity Fund, L.P. (CPGEF). Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | PurchaseCommon Stock | 850,000 | $15.00 | $12,750,000.00 |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 3,224,849 F1 · ownership.nature: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 18:33 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | ConversionCommon Stock | 2,374,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-049765 · doc4.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · 10% owner Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner Casdin Capital, LLC · CIK 0001534261 · 10% owner CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 2,374,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.nature: These shares are held directly by Casdin Partners Master Fund, L.P.(CPMF). F2 · ownership.nature: Casdin Capital, LLC is the investment advisor to CPMF and CPGEF. Casdin Partners GP, LLC is the general partner of CPMF. Casdin Private Growth Equity Fund GP, LLC is the general partner of CPGEF. The Reporting Person is the managing member of Casdin Capital, LLC, Casdin Partners GP, LLC and Casdin Private Growth Equity Fund GP, LLC and may be deemed to have voting and investment power with respect to the shares. The Reporting Person disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein, if any. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $13.12 | $12,769,178.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · derivative · entry 7 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 973,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F3 · derivative.expiration_date: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4 · ownership.nature: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionConvertible Note · Derivative | Not disclosed | $0.00 Strike: $13.12 | $12,769,178.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · derivative · entry 6 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 973,260 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F3 · derivative.expiration_date: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2 · ownership.direct: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionSeries E Preferred Stock · Derivative | 1,274,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · derivative · entry 5 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,209,573 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F1 · derivative.exercise_date: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F1 · derivative.expiration_date: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionCommon Stock | 973,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · nonDerivative · entry 4 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 973,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F4 · ownership.nature: These shares are held by Casdin Private Growth Equity Fund, L.P. Casdin Capital is the investment adviser to Casdin Private Growth Equity Fund, L.P. and Casdin Private Growth Equity Fund GP, LLC ("Casdin Private Growth GP") is the general partner of Casdin Private Growth Equity Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Private Growth GP. Each of Casdin Capital, Casdin Private Growth GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports. Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | PurchaseCommon Stock | 1,562,500 | $16.00 | $25,000,000.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · nonDerivative · entry 3 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,745,333 F2 · ownership.direct: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionCommon Stock | 973,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · nonDerivative · entry 2 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,182,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · price: This convertible promissory note ("Convertible Note") had a maturity date of September 16, 2023. The principal and accrued interest under the Convertible Note converted upon the closing of the IPO into shares of Common Stock at a conversion price equal to $13.12 per share without payment of additional consideration. F2 · ownership.direct: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Read SEC document |
| July 26, 2021 Filed Jul 28, 2021 16:33 UTC | Absci Corp ABSI · Entity 4685 | ConversionCommon Stock | 4,209,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-21-014732 · wf-form4_162750420600927.xml · nonDerivative · entry 1 Casdin Partners Master Fund, L.P. · CIK 0001534265 · Director Casdin Capital, LLC · CIK 0001534261 · Director Casdin Partners GP, LLC · CIK 0001534260 · Director Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · Director CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC · CIK 0001864554 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,209,573 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: These shares of the Series E Preferred Stock automatically converted on a one-for-3.3031 basis into the number of shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock"), shown in Column 7 immediately upon closing of the Issuer's initial public offering ("IPO") without payment of additional consideration. The Series E Preferred Stock had no expiration date. F2 · ownership.direct: These shares are held by Casdin Partners Master Fund, L.P. Casdin Capital, LLC ("Casdin Capital") is the investment adviser to Casdin Partners Master Fund, L.P., and Casdin Partners GP, LLC ("Casdin Partners GP") is the general partner of Casdin Partners Master Fund, L.P. Eli Casdin is the managing member of Casdin Capital and Casdin Partners GP. Each of Casdin Capital, Casdin Partners GP and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein, if any. Eli Casdin is a director of the Issuer and, accordingly, files separate Section 16 reports Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:12 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionSeries B Preferred Stock · Derivative | 5,746,183 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025300 · doc4.xml · derivative · entry 2 Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 620,571 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.direct: The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. Read SEC document |
| June 21, 2021 Filed Jun 22, 2021 17:12 UTC | Verve Therapeutics, Inc. VERV · Entity 11259 | ConversionCommon Stock | 620,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-025300 · doc4.xml · nonDerivative · entry 1 Casdin Private Growth Equity Fund, L.P. · CIK 0001823061 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 620,571 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series B Preferred Stock converted into shares of the Issuer's common stock, $0.001 par value, on an approximately 9.2595:1 basis automatically immediately prior to the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. F2 · ownership.direct: The shares reflected as beneficially owned by Casdin Private Growth Equity Fund, L.P. are owned directly by Casdin Private Growth Equity Fund, L.P. and may be deemed to be indirectly beneficially owned by (i) Casdin Capital, LLC, the investment adviser to Casdin Private Growth Equity Fund, L.P., (ii) Casdin Partners GP, LLC, the general partner of Casdin Private Growth Equity Fund L.P., and (iii) Eli Casdin, the managing member of Casdin Capital, LLC and Casdin Partners GP, LLC. Each of Casdin Capital, LLC, Casdin Partners GP, LLC and Eli Casdin disclaims beneficial ownership of such securities except to the extent of their respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.